Prevalence of HPV in Anal Cancer: Exploring the Role of Infection and Inflammation

Overview

Journal Infect Agent Cancer

Publisher Biomed Central

Specialty Infectious Diseases

Date 2024 Dec 19

PMID 39696546

Authors

Fatemeh Ebrahimi

Reyhaneh Rasizadeh

Sajjad Jafari

Hossein Bannazadeh Baghi

Affiliations

Soon will be listed here.

Abstract

Anal cancer incidence is rising globally, driven primarily by human papillomavirus (HPV) infection. HPV, especially high-risk types 16 and 18, is considered a necessary cause of anal squamous cell carcinoma. Certain populations like people living with HIV, men who have sex with men, inflammatory bowel disease patients, smokers, and those with compromised immunity face elevated risk. Chronic inflammation facilitates viral persistence, cell transformation, and immune evasion through pathways involving the PD-1/PD-L1 axis. HIV coinfection further increases risk by impairing immune surveillance and epithelial integrity while promoting HPV oncogene expression. Understanding these inflammatory processes, including roles of CD8 + T cells and PD-1/PD-L1, could guide development of immunotherapies against anal cancer. This review summarizes current knowledge on inflammation's role in anal cancer pathogenesis and the interplay between HPV, HIV, and host immune factors.

References

Xiao W, Yuan Y, Wang S, Liao Z, Cai P, Chen B . Neoadjuvant PD-1 Blockade Combined With Chemotherapy Followed by Concurrent Immunoradiotherapy in Locally Advanced Anal Canal Squamous Cell Carcinoma Patients: Antitumor Efficacy, Safety and Biomarker Analysis. Front Immunol. 2022; 12:798451. PMC: 8794813. DOI: 10.3389/fimmu.2021.798451. View

Chiao E, Krown S, Stier E, Schrag D . A population-based analysis of temporal trends in the incidence of squamous anal canal cancer in relation to the HIV epidemic. J Acquir Immune Defic Syndr. 2005; 40(4):451-5. DOI: 10.1097/01.qai.0000159669.80207.12. View

Fridman W, Pages F, Sautes-Fridman C, Galon J . The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer. 2012; 12(4):298-306. DOI: 10.1038/nrc3245. View

Balermpas P, Martin D, Wieland U, Rave-Frank M, Strebhardt K, Rodel C . Human papilloma virus load and PD-1/PD-L1, CD8 and FOXP3 in anal cancer patients treated with chemoradiotherapy: Rationale for immunotherapy. Oncoimmunology. 2017; 6(3):e1288331. PMC: 5384387. DOI: 10.1080/2162402X.2017.1288331. View

Bucktrout S, Bluestone J, Ramsdell F . Recent advances in immunotherapies: from infection and autoimmunity, to cancer, and back again. Genome Med. 2018; 10(1):79. PMC: 6208073. DOI: 10.1186/s13073-018-0588-4. View

Saraiya M, Unger E, Thompson T, Lynch C, Hernandez B, Lyu C . US assessment of HPV types in cancers: implications for current and 9-valent HPV vaccines. J Natl Cancer Inst. 2015; 107(6):djv086. PMC: 4838063. DOI: 10.1093/jnci/djv086. View

Ogawa H, Haneda S, Shibata C, Miura K, Nagao M, Ohnuma S . Adenocarcinoma associated with perianal fistulas in Crohn's disease. Anticancer Res. 2013; 33(2):685-9. View

Aghbash P, Rasizadeh R, Yari A, Lahouti S, MotieGhader H, Nahand J . Interleukin-2 and Oncolytic Virotherapy: A New Perspective in Cancer Therapy. Anticancer Agents Med Chem. 2023; 23(18):2008-2026. DOI: 10.2174/1871520623666230727095154. View

Deshmukh A, Suk R, Shiels M, Sonawane K, Nyitray A, Liu Y . Recent Trends in Squamous Cell Carcinoma of the Anus Incidence and Mortality in the United States, 2001-2015. J Natl Cancer Inst. 2019; 112(8):829-838. PMC: 7825484. DOI: 10.1093/jnci/djz219. View

10.

Ruel J, Ko H, Roda G, Patil N, Zhang D, Jharap B . Anal Neoplasia in Inflammatory Bowel Disease Is Associated With HPV and Perianal Disease. Clin Transl Gastroenterol. 2016; 7:e148. PMC: 4822100. DOI: 10.1038/ctg.2016.8. View

11.

Haas C, Engels E, Horner M, Pfeiffer R, Luo Q, Kreimer A . Cumulative incidence of anal cancer since HIV or AIDS diagnosis in the United States. J Natl Cancer Inst. 2023; 115(10):1227-1230. PMC: 10560593. DOI: 10.1093/jnci/djad128. View

12.

Barber D, Wherry E, Masopust D, Zhu B, Allison J, Sharpe A . Restoring function in exhausted CD8 T cells during chronic viral infection. Nature. 2005; 439(7077):682-7. DOI: 10.1038/nature04444. View

13.

Ciombor K, Ernst R, Brown G . Diagnosis and Diagnostic Imaging of Anal Canal Cancer. Surg Oncol Clin N Am. 2016; 26(1):45-55. PMC: 10174401. DOI: 10.1016/j.soc.2016.07.002. View

14.

Allouch S, Malki A, Allouch A, Gupta I, Vranic S, Moustafa A . High-Risk HPV Oncoproteins and PD-1/PD-L1 Interplay in Human Cervical Cancer: Recent Evidence and Future Directions. Front Oncol. 2020; 10:914. PMC: 7338567. DOI: 10.3389/fonc.2020.00914. View

15.

Winkler R, Wittmer A, Heusermann U . [Cancer and Crohn's disease]. Z Gastroenterol. 2002; 40(8):569-76. DOI: 10.1055/s-2002-33417. View

16.

Voiculescu V, Lisievici C, Lupu M, Vajaitu C, Draghici C, Popa A . Mediators of Inflammation in Topical Therapy of Skin Cancers. Mediators Inflamm. 2019; 2019:8369690. PMC: 6350587. DOI: 10.1155/2019/8369690. View

17.

Shaw J, Hanley S, Sitnik E, Berry W, Blatt S, Seserman M . Attitudes towards HPV Vaccination Policy Strategies to Improve Adolescent Vaccination Coverage among Pediatric Providers in New York State. Vaccines (Basel). 2023; 11(8). PMC: 10457785. DOI: 10.3390/vaccines11081359. View

18.

Salati S, Al Kadi A . Anal cancer - a review. Int J Health Sci (Qassim). 2013; 6(2):206-30. PMC: 3616949. DOI: 10.12816/0006000. View

19.

Strickler H, Burk R, Fazzari M, Anastos K, Minkoff H, Massad L . Natural history and possible reactivation of human papillomavirus in human immunodeficiency virus-positive women. J Natl Cancer Inst. 2005; 97(8):577-86. DOI: 10.1093/jnci/dji073. View

20.

Blackburn S, Shin H, Nicholas Haining W, Zou T, Workman C, Polley A . Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection. Nat Immunol. 2008; 10(1):29-37. PMC: 2605166. DOI: 10.1038/ni.1679. View